Analysts say Eli Lilly may have a future blockbuster drug on its hands: An experimental pill designed to lower ... so lifestyle changes such as diet or exercise have no effect, Ruth Gimeno ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug ... Zepbound should be used in combination with a reduced-calorie diet and increased physical activity, the ...
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by ...
CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.